| Market Cap | ₹1,162.57 CrSmall Cap |
|---|---|
| TTM Revenue | ₹2,012.58 CrSpecialty Chemicals |
| Promoter Holding | 63.31%Stable holding |
| Day RSI | 37.33Neutral zone |
Key highlights
- US patent granted for a novel class of compounds targeting cancer and cancer stem cells
- Invention shows specific potential against breast and prostate cancer types
- Lead anti-cancer molecule MSP008-22 efficacy trials scheduled to start in Q3 FY27
- Company targeting a 3x EBITDA expansion by FY29 via Rs 325 crore planned capex
- Operating revenue stood at Rs 557.88 crore for the quarter ended June 30, 2026
US Patent Grant for Oncology Research
Godavari Biorefineries has achieved a significant milestone in its pharmaceutical research with the grant of a United States patent for its invention titled 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER. This patent protects a novel class of compounds that effectively inhibit cancer and cancer stem cells. The research highlights significant potential across various cancer types, specifically showing efficacy against breast and prostate cancers.
The grant provides long-term intellectual property protection in the US market, which is critical for the potential commercialization or licensing of these novel oncology compounds.
Financial Performance and Growth Targets
- Operating revenue for the June 2026 quarter reached Rs 557.88 crore, a 4.62% increase year-on-year.
- The company reported a net loss of Rs 19.32 crore for the quarter, compared to a loss of Rs 16.02 crore in the same period last year.
- Annual trailing twelve-month (TTM) operating revenue is recorded at Rs 2,012.58 crore.
- The stock is trading at a P/E TTM of 5,161.78 against an industry average of 46.47.
- Management has guided for a planned capital expenditure of Rs 325 crore to achieve scale by FY29.
- Promoter holding remains steady at 63.31% with no pledged shares reported.
Clinical Pipeline and Strategic Roadmap
The patent grant aligns with the company's established research roadmap. Godavari Biorefineries previously indicated that preliminary efficacy trials for its lead anti-cancer molecule, MSP008-22, are scheduled to commence in Q3 FY27, subject to CDSCO regulatory approval in India. By securing this US patent, the company strengthens its biopharmaceutical portfolio as it moves through the clinical trial stages.
This development supports the firm's broader strategy to diversify its specialty chemicals business into high-value pharmaceutical applications, backed by its ongoing investment in R&D and planned capacity expansions through FY29.
What to watch next
- Commencement of preliminary efficacy trials for molecule MSP008-22 in Q3 FY27
- Regulatory approval from the CDSCO for clinical milestones
- Progress on the Rs 325 crore capex plan for EBITDA expansion
- Upcoming quarterly financial results to monitor operating margin recovery
| Share price | ₹227.17 |
|---|---|
| Market capitalisation | ₹1,162.57 Cr |
| Revenue (annual) | ₹1,987.94 Cr |
| Net profit (annual) | ₹3.53 Cr |
| Revenue (latest quarter) | ₹557.88 Cr-1.10% vs previous quarter |
| Net profit (latest quarter) | -₹19.32 Cr-136.53% vs previous quarter |
| P/E (TTM) | 5161.78×Sector 36.63× |
| Promoter holding | 63.31%0.00% QoQ |
| FII holding | 0.22%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Godavari Biorefineries Ltd announcing the grant of a US patent for cancer treatment compounds. Market figures from a third-party data provider.
Track Godavari Biorefineries live
Get the next Godavari Biorefineries filing on Telegram seconds after it lands. 15 days free.
